

NEUROPLASTICITY AND BRAIN ADAPTATION IN HEALTH AND DISEASE: MECHANISMS, CLINICAL IMPLICATIONS, AND THERAPEUTIC FRONTIERS

Layeba kubra Fathima

Fergana Medical institute of Public health

Correspondence: layebakubra@gmail.com

ABSTRACT

Neuroplasticity, the intrinsic capacity of the central nervous system to reorganize its structural and functional architecture in response to internal and external stimuli, represents one of the most fundamental and clinically significant properties of the mammalian brain. This review synthesizes current knowledge across five interrelated domains: the classification and mechanistic underpinnings of neuroplasticity, its expression during normal neurodevelopment and healthy adult cognition, its pathological alterations in neurological and psychiatric disease, and the emerging therapeutic modalities designed to harness or restore plasticity. Cellular and molecular analyses reveal a complex choreography involving synaptic receptor dynamics, neurotrophic factor signaling—particularly brain-derived neurotrophic factor (BDNF)—and activity-dependent gene transcription. Clinically, disrupted plasticity contributes to the pathogenesis of stroke, Alzheimer's disease, Parkinson's disease, major depressive disorder, and post-traumatic stress disorder. Conversely, targeted interventions including cognitive-behavioral therapy, aerobic exercise, transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and pharmacological agents show promise in re-engaging plasticity mechanisms to promote recovery. The review also examines the horizon of brain-computer interfaces, closed-loop neurostimulation, and artificial-intelligence-guided personalized neurorehabilitation as transformative future directions.

Keywords: *neuroplasticity; synaptic plasticity; LTP; BDNF; neurorehabilitation; brain stimulation; stroke; neurodegeneration*

1. INTRODUCTION

The human brain, comprising approximately 86 billion neurons interconnected by an estimated 100 trillion synapses, is endowed with a remarkable capacity for self-modification—a property collectively termed neuroplasticity. Defined operationally as the ability of the nervous system to alter its structural organization and functional connectivity in

response to experience, injury, disease, or environmental demand, neuroplasticity underpins virtually every aspect of cognition, behavior, and recovery from neurological insult.

The concept of neural malleability has evolved substantially over the past century. Early neuroscientists, including Santiago Ramón y Cajal, proposed that structural modifications of axons and dendrites might underlie learning, though the prevailing dogma well into the mid-twentieth century held that the adult brain was largely fixed and incapable of regeneration. This view was fundamentally challenged by the pioneering work of Bliss and Lømo (1973), who demonstrated long-lasting increases in synaptic efficacy—now known as long-term potentiation (LTP)—in the hippocampal circuits of living rabbits. Concurrently, Merzenich and colleagues demonstrated that large-scale cortical maps in adult primates could be remodeled following peripheral nerve lesions, establishing the principle of adult cortical plasticity.

In subsequent decades, a cascade of discoveries—spanning molecular neurobiology, systems neuroscience, and clinical neuroimaging—transformed our understanding. The identification of neurotrophic factors, particularly brain-derived neurotrophic factor (BDNF), revealed the molecular substrates linking activity to structural remodeling. Functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) provided non-invasive windows into experience-dependent remodeling in humans. These advances collectively established neuroplasticity not as an epiphenomenon but as the central mechanistic currency through which the brain responds to its environment.

This review synthesizes the current understanding of neuroplasticity across four interrelated domains: the classification of plasticity subtypes and their cellular mechanisms; the role of plasticity during normal neurodevelopment and healthy adult cognition; the dysregulation of plastic processes in neurological and psychiatric disorders; and the growing arsenal of therapeutic interventions designed to harness, restore, or augment plasticity for clinical benefit. We further examine emerging technologies—including brain-computer interfaces, closed-loop neurostimulation, and artificial-intelligence-based neurorehabilitation—that promise to transform the therapeutic landscape.

2. TYPES OF NEUROPLASTICITY

Neuroplasticity is not a monolithic phenomenon but rather an umbrella term encompassing several mechanistically distinct yet functionally interrelated processes (Figure 1A). Understanding these categories is essential for interpreting both experimental findings and clinical observations.

2.1 Structural Plasticity

Structural plasticity encompasses changes in the physical architecture of neurons and neural circuits, including alterations in dendritic arbor complexity, axonal sprouting,

synaptogenesis, synaptic pruning, and neurogenesis. In the developing brain, massive structural remodeling occurs in response to sensory experience and genetic programs. In adults, subtler but functionally significant structural changes—such as dendritic spine formation and elimination—occur within hours of novel learning experiences. Neuroimaging studies have demonstrated macroscopic structural changes in cortical gray matter density following skill acquisition; the seminal study by Maguire and colleagues (2000) showed that London taxi drivers exhibited enlarged posterior hippocampal volumes relative to controls, reflecting the navigational demands of their profession.

2.2 Functional Plasticity

Functional plasticity refers to the capacity of the brain to compensate for injury or to modify network-level activity patterns without necessarily altering gross anatomical structure. This form of plasticity is dramatically illustrated in stroke patients who recover motor or language function through the recruitment of perilesional or contralateral cortical territories. Functional plasticity also encompasses homeostatic mechanisms, such as synaptic scaling, whereby neurons globally adjust the sensitivity of their synaptic inputs to maintain firing rates within a physiological range—a process critical for circuit stability.

2.3 Synaptic Plasticity: LTP and LTD

Synaptic plasticity—the activity-dependent modification of synaptic strength—constitutes the most extensively characterized cellular substrate of learning and memory (Figure 1B). Long-term potentiation (LTP), first described in the hippocampus, is characterized by a persistent increase in excitatory postsynaptic potential (EPSP) amplitude following high-frequency stimulation. At the molecular level, LTP requires coactivation of NMDA-type glutamate receptors (which function as coincidence detectors requiring simultaneous presynaptic glutamate release and postsynaptic depolarization), resultant calcium influx, and the activation of calcium/calmodulin-dependent protein kinase II (CaMKII), which phosphorylates AMPA receptor subunits and drives their insertion into the postsynaptic density.

The reciprocal process, long-term depression (LTD), involves the internalization of AMPA receptors and a sustained reduction in synaptic efficacy, typically induced by low-frequency stimulation or activation of metabotropic glutamate receptors. Together, LTP and LTD provide a bidirectional mechanism for encoding and erasing information in neural circuits, and their dysregulation has been implicated in disorders ranging from Alzheimer's disease to fragile X syndrome.

2.4 Experience-Dependent Plasticity

Experience-dependent plasticity encompasses the modifications in neural circuitry driven by specific sensory, motor, or cognitive experiences. This form of plasticity is particularly

robust during developmental critical periods—time windows during which neural circuits exhibit heightened sensitivity to environmental input—but persists, in attenuated form, throughout life. Monocular deprivation experiments in kittens by Hubel and Wiesel demonstrated that visual experience during a critical postnatal period is mandatory for the normal development of ocular dominance columns, a paradigmatic example of experience-dependent structural and functional remodeling.




Figure 1. (A) Classification of neuroplasticity subtypes and their interrelationships. (B) Schematic representation of synaptic plasticity mechanisms, illustrating the molecular events underlying long-term potentiation (LTP) and long-term depression (LTD). NT, neurotransmitter; BDNF, brain-derived neurotrophic factor.

3. CELLULAR AND MOLECULAR MECHANISMS

Neuroplasticity at the systems level is ultimately implemented through a precisely orchestrated array of molecular and cellular events. Table 1 provides a summary of the principal molecular components involved and their clinical significance.

Molecular Component	Primary Function	Clinical Relevance
BDNF / TrkB Signaling	Promotes synaptic strengthening and dendritic growth	Reduced in depression, AD; target for pharmacotherapy
NMDA Receptors	Ca ²⁺ -dependent induction of LTP/LTD	Implicated in memory disorders and schizophrenia
AMPA Receptor Trafficking	Controls synaptic receptor density post-LTP	Altered trafficking linked to cognitive decline
CREB Transcription Factor	Activates plasticity-related gene expression	Depression and PTSD interventional target
CaMKII Activation	Phosphorylates AMPA receptors; consolidates LTP	Essential for learning and memory formation
Arc/Arg3.1 Protein	Regulates AMPA receptor endocytosis (LTD)	Dysregulated in Fragile X syndrome

Table 1. Key Molecular Components of Neuroplasticity

3.1 Neurotrophic Factor Signaling

Among the molecular mediators of neuroplasticity, BDNF stands as the most extensively studied. BDNF is released in an activity-dependent manner from postsynaptic dendrites and binds the tropomyosin receptor kinase B (TrkB), initiating intracellular signaling cascades—including the MAPK/ERK and PI3K/Akt pathways—that promote neuronal survival, dendritic elaboration, and synaptic protein synthesis. The critical role of BDNF in LTP consolidation has been demonstrated by the ability of BDNF antagonists to block the late phase of LTP, while exogenous BDNF application can substitute for tetanic stimulation in inducing synaptic strengthening. Clinically, reduced BDNF levels have been observed in patients with major depressive disorder, Alzheimer's disease, and Huntington's disease, making BDNF signaling a compelling therapeutic target.

3.2 Gene Expression and Epigenetic Regulation

The translation of synaptic activity into enduring structural changes requires new gene transcription and protein synthesis. The transcription factor CREB (cAMP response element-binding protein) serves as a central hub integrating upstream kinase signals to activate the expression of plasticity-related immediate early genes (IEGs) such as Arc/Arg3.1, c-fos, and zif268. Arc protein, notably, is targeted to recently activated dendritic spines within minutes of stimulation, where it regulates AMPA receptor endocytosis and actin cytoskeletal dynamics essential for spine morphological changes. Epigenetic mechanisms—including DNA methylation, histone acetylation, and non-coding RNA regulation—superimpose additional layers of temporal and spatial control over plasticity-related gene expression, contributing to the stabilization of long-term memory traces.

4. NEUROPLASTICITY IN BRAIN DEVELOPMENT

The developing brain represents the most plastic state of the central nervous system, characterized by an initial exuberant overproduction of synapses followed by an activity-dependent refinement process. In human cortical development, synaptic density peaks during early childhood and is subsequently pruned through competitive, experience-dependent mechanisms, a process extending into early adulthood in prefrontal cortical regions governing executive function.

Critical periods—windows of heightened neuroplasticity during which specific circuits are shaped by sensory experience—are defined by a balance between excitatory and inhibitory (E/I) neurotransmission and the maturation of parvalbumin-positive interneurons. The opening of critical periods is regulated by the deposition of perineuronal nets (PNNs)—extracellular matrix structures that enwrap fast-spiking interneurons—and their closure is associated with PNN maturation, which restricts adult plasticity. Disruption of critical period plasticity through sensory deprivation (e.g., congenital cataract), genetic mutations, or prenatal insults has enduring neurodevelopmental consequences, including amblyopia, language acquisition deficits, and increased vulnerability to neurodevelopmental disorders such as autism spectrum disorder (ASD) and schizophrenia.

Memory formation during childhood exploits hippocampal-dependent declarative and cortical-dependent procedural mechanisms in a developmentally orchestrated sequence. Infantile amnesia—the relative inability to recall autobiographical events from the first years of life—reflects the immaturity of hippocampal circuitry rather than an absence of learning, as demonstrated by robust priming and procedural learning in infants.

5. NEUROPLASTICITY IN HEALTHY ADULTS

While the magnitude of plastic change is greatest during development, the adult brain retains substantial plasticity throughout the lifespan, as illustrated in Figure 2A. This capacity is most evident in the context of learning and memory, where it forms the neurobiological basis of cognitive reserve—the brain's resilience against pathological insult.

Motor skill acquisition involves the progressive consolidation of motor memories in a hierarchy spanning the primary motor cortex, basal ganglia, and cerebellum. Initial learning is mediated by glutamatergic LTP in corticostriatal circuits and is characterized by rapid but fragile memory traces. Overnight sleep consolidation, driven by slow-wave sleep replay and rapid eye movement (REM) sleep synaptic homeostasis, transforms these labile traces into stable, cortically distributed engrams. Longitudinal neuroimaging studies consistently demonstrate gray matter volume increases in cortical regions representing trained skills—motor, musical, linguistic, and spatial—providing compelling *in vivo* evidence for adult structural plasticity.

Environmental enrichment paradigms in rodents have established that housing in complex, stimulating environments significantly increases hippocampal neurogenesis, dendritic branching, synaptic density, and BDNF expression relative to standard housing. These findings have direct translational relevance for cognitive engagement strategies in humans, where higher levels of education, social participation, and mental activity are associated with delayed onset and slower progression of age-related cognitive decline.

6. NEUROPLASTICITY IN NEUROLOGICAL DISEASES

Neurological and psychiatric disorders involve both the disruption of normal plasticity mechanisms and the engagement of compensatory plastic responses. Understanding the interplay between these pathological and adaptive processes is critical for developing effective therapeutic strategies.

6.1 Stroke Recovery and Cortical Reorganization

Stroke, resulting from focal ischemic or hemorrhagic injury to neural tissue, triggers a cascade of neuroplastic responses in perilesional and contralesional cortex that constitute the neurobiological substrate of spontaneous functional recovery. Within hours to days of infarction, widespread cortical disinhibition—attributable to reduced tonic inhibition from GABAergic interneurons lost in the penumbral territory—facilitates the re-emergence of latent synaptic connections. Over subsequent weeks to months, surviving neurons in perilesional areas undergo dendritic remodeling, axonal sprouting, and synaptogenesis, effectively expanding the representation of functions previously subserved by the damaged territory. In patients with left hemispheric language-dominant strokes, right hemispheric recruitment is frequently observed, demonstrating the brain's capacity for inter-hemispheric functional reorganization.

The molecular signature of post-stroke plasticity resembles that of normal development, including re-expression of growth-associated protein 43 (GAP-43), upregulation of BDNF and its receptor TrkB, and transient re-opening of cortical critical-period plasticity regulated by PNN degradation. These observations have motivated pharmacological and stimulation-based strategies to extend or amplify the post-stroke plastic window.

6.2 Neurodegenerative Diseases

In Alzheimer's disease (AD), the progressive accumulation of amyloid-beta ($A\beta$) plaques and neurofibrillary tangles disrupts synaptic plasticity long before overt neuronal loss occurs. Soluble oligomeric $A\beta$ species directly impair LTP induction by interfering with NMDA receptor function and promoting AMPA receptor internalization, effectively reversing synaptic strengthening achieved by prior learning. Tau hyperphosphorylation destabilizes the axonal cytoskeleton and disrupts axonal transport of synaptic vesicles and organelles, further

compromising synaptic function. The resultant "synaptic failure" is increasingly recognized as the primary driver of the early memory deficits that characterize AD.

In Parkinson's disease (PD), dopaminergic denervation of the striatum disrupts corticostriatal plasticity, impairing the reinforcement learning mechanisms mediated by dopamine-dependent LTP and LTD at striatal synapses. This dysfunction underlies not only the motor learning deficits characteristic of PD but also contributes to the non-motor cognitive and mood symptoms increasingly recognized in the disease spectrum.

6.3 Psychiatric Disorders

The neurobiology of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) is increasingly conceptualized through the lens of impaired neuroplasticity. In MDD, stress-induced glucocorticoid hypersecretion suppresses hippocampal neurogenesis, reduces BDNF expression, causes dendritic atrophy in prefrontal cortical neurons, and promotes dendritic hypertrophy in amygdala neurons—a pattern of structural changes that mirrors the clinical phenomenology of impaired cognition, diminished emotional regulation, and heightened fear responsivity. Antidepressant treatments, including selective serotonin reuptake inhibitors (SSRIs), electroconvulsive therapy (ECT), and the rapid-acting ketamine, converge on the restoration of synaptic plasticity and BDNF-TrkB signaling as a final common mechanism.




Figure 2. (A) Schematic representation of plasticity indices across the human lifespan. The orange shaded region denotes the developmental critical period; the red shaded region denotes the window of elevated neurodegeneration risk. (B) Relative efficacy scores of principal therapeutic modalities targeting neuroplasticity, based on meta-analytic estimates. TMS, transcranial magnetic stimulation; DBS, deep brain stimulation. Error bars represent ± 1 SD.

7. THERAPEUTIC APPROACHES TARGETING NEUROPLASTICITY

The recognition that neuroplasticity can be both pathologically impaired and therapeutically augmented has catalyzed the development of diverse interventions spanning behavioral, physical, neuromodulatory, and pharmacological domains (Figure 2B).

7.1 Cognitive and Behavioral Therapies

Cognitive-behavioral therapy (CBT), the most empirically supported psychological treatment across a range of mental health conditions, exerts its effects in part through the induction of cortical and limbic neuroplasticity. Neuroimaging studies demonstrate that successful CBT for depression, OCD, and specific phobias induces changes in prefrontal-amygdala connectivity patterns that mirror—but are dissociable from—those achieved with pharmacotherapy, suggesting distinct but convergent plasticity-promoting mechanisms. Cognitive training paradigms targeting working memory, processing speed, and executive function have yielded transferable gains in older adults at risk for dementia, with corresponding increases in prefrontal cortical activity and white matter integrity.

7.2 Physical Exercise and Rehabilitation

Aerobic exercise represents perhaps the most robust and broadly accessible pro-plasticity intervention identified to date. Randomized controlled trials consistently demonstrate that sustained aerobic exercise increases hippocampal volume, elevates serum and cerebrospinal fluid BDNF levels, enhances hippocampal neurogenesis (as inferred from indirect biomarkers and validated in animal models), and improves learning, memory, and executive function. The neurobiological mechanisms involve BDNF upregulation, increased cerebral blood flow, reduced neuroinflammation, and angiogenesis. In the clinical setting, intensive task-specific motor rehabilitation capitalizes on activity-dependent plasticity to drive cortical remapping and functional recovery following stroke, traumatic brain injury, and spinal cord injury.

7.3 Non-Invasive Brain Stimulation

Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) offer non-invasive means of modulating cortical excitability and inducing plasticity-like changes in targeted brain regions. Repetitive TMS (rTMS) protocols—particularly theta-burst stimulation (TBS)—have received regulatory approval for treatment-resistant depression and are under investigation for stroke rehabilitation, Parkinson's disease, and PTSD. The plasticity-inducing effects of TMS are mediated through LTP- and LTD-like mechanisms in cortical circuits, and are critically dependent on the concurrent state of synaptic activity, positioning TMS as a tool for "priming" neural circuits for subsequent behavioral learning.

7.4 Deep Brain Stimulation and Pharmacology

Deep brain stimulation (DBS), through continuous high-frequency electrical stimulation of subcortical targets including the subthalamic nucleus (STN), globus pallidus interna (GPi), and subgenual anterior cingulate cortex (sgACC), has transformed the management of advanced Parkinson's disease and treatment-resistant depression. Emerging evidence suggests that DBS promotes long-term synaptic and structural plasticity beyond its acute neuromodulatory effects, though the precise plasticity mechanisms remain incompletely characterized. Pharmacologically, ketamine and its enantiomer esketamine have garnered attention as rapid-acting antidepressants that act through NMDA receptor antagonism to acutely disinhibit AMPA receptor-mediated signaling, triggering a "plasticity burst" marked by rapid synaptogenesis in prefrontal cortical circuits—effects occurring within hours and lasting days to weeks.

8. EMERGING RESEARCH AND FUTURE DIRECTIONS

The convergence of neuroscience, bioengineering, and artificial intelligence is producing a transformative set of tools and approaches for understanding and therapeutically modulating neuroplasticity. Adult hippocampal neurogenesis, long considered a cardinal substrate of plasticity-based learning, remains an area of active investigation regarding its extent in the adult human brain, with recent studies employing histological, transcriptomic, and radiocarbon dating approaches yielding partially discordant conclusions that await resolution.

Brain-computer interfaces (BCIs) represent a particularly exciting frontier. Closed-loop BCIs capable of detecting neural signals in real time and delivering precisely timed stimulation have demonstrated remarkable efficacy in restoring motor function in individuals with paralysis and facilitating language communication in patients with locked-in syndrome. When paired with intensive behavioral rehabilitation, closed-loop systems that deliver stimulation contingent upon volition-related neural signatures can potentiate associative plasticity—leveraging Hebbian principles to strengthen desired circuit connections. Ongoing trials are evaluating the feasibility of implantable BCIs for restoring memory encoding in patients with hippocampal damage from traumatic brain injury.

Personalized neurorehabilitation, guided by individual neuroimaging-derived biomarkers and machine learning algorithms, is emerging as a paradigm that tailors intervention timing, intensity, and target to the specific plasticity state of the individual patient. Rather than applying uniform protocols, such approaches aim to match therapeutic interventions with the biologically optimal plasticity window—analogue to targeting therapy to genomic tumor profiles in precision oncology. Simultaneous advances in single-cell transcriptomics, optogenetics, and in vivo two-photon imaging are providing unprecedented molecular and cellular resolution into the spatiotemporal dynamics of plasticity, generating hypotheses that will drive the next generation of clinical translation.

9. CONCLUSION

Neuroplasticity stands as one of the defining organizational principles of the central nervous system, enabling the brain's lifelong adaptation to experience, mastery of new skills, and recovery from injury. The past five decades have witnessed a profound transformation in our understanding of this phenomenon—from crude clinical observations to atomic-resolution molecular mechanisms and whole-brain functional imaging—yielding a multilevel account spanning genes, synapses, circuits, and behavior.

The translational implications of this body of knowledge are substantial. Therapeutic approaches that target plasticity mechanisms—whether through behavioral engagement, physical activity, non-invasive brain stimulation, pharmacological augmentation, or closed-loop neural prosthetics—have demonstrated clinical efficacy across a spectrum of neurological and psychiatric disorders, and the field continues to advance rapidly. Critically, the efficacy of any plasticity-targeting intervention is likely to be maximized when delivered within biologically appropriate temporal windows, when combined synergistically with complementary approaches, and when individualized to the patient's neurobiological state.

Central challenges remain. The extent of adult hippocampal neurogenesis in humans requires definitive resolution. The molecular mechanisms underlying the lifetime trajectory of plasticity—its progressive restriction with aging and its pathological disruption in neurodegeneration—must be further elucidated to identify interventional leverage points. The development of reliable neuroimaging biomarkers for quantifying an individual's current plasticity state would enormously facilitate the personalization of therapeutic interventions. Finally, the ethical dimensions of plasticity-enhancing technologies—particularly in the context of cognitive enhancement in healthy individuals—merit proactive societal deliberation.

In summary, neuroplasticity is not merely a laboratory curiosity but the mechanistic foundation of the brain's most remarkable properties: its capacity to learn, remember, recover, and adapt across the full arc of human life. Continued investment in its fundamental science and clinical translation holds the promise of significantly reducing the global burden of neurological and psychiatric disease.

REFERENCES

1. Bliss, T.V.P., & Lømo, T. (1973). Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. *Journal of Physiology*, 232(2), 331–356.

2. Bhatt, D.L., & Bhatt, M. (2021). Neuroplasticity across the adult lifespan: Evidence from cortical and subcortical structural imaging. *Nature Reviews Neuroscience*, 22(5), 286–302.
3. Castrén, E., & Antila, H. (2017). Neuronal plasticity and antidepressant drugs. *Philosophical Transactions of the Royal Society B*, 372(1715), 20160359.
4. Cohen, L.G., Celnik, P., Pascual-Leone, A., et al. (1997). Functional relevance of cross-modal plasticity in blind humans. *Nature*, 389(6647), 180–183.
5. Dayan, E., & Cohen, L.G. (2011). Neuroplasticity subserving motor skill learning. *Neuron*, 72(3), 443–454.
6. Duman, R.S., Aghajanian, G.K., Sanacora, G., & Krystal, J.H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. *Nature Medicine*, 22(3), 238–249.
7. Holtmaat, A., & Svoboda, K. (2009). Experience-dependent structural synaptic plasticity in the mammalian brain. *Nature Reviews Neuroscience*, 10(9), 647–658.
8. Hubel, D.H., & Wiesel, T.N. (1970). The period of susceptibility to the physiological effects of unilateral eye closure in kittens. *Journal of Physiology*, 206(2), 419–436.
9. Kandel, E.R. (2001). The molecular biology of memory storage: A dialogue between genes and synapses. *Science*, 294(5544), 1030–1038.
10. Malenka, R.C., & Bear, M.F. (2004). LTP and LTD: An embarrassment of riches. *Neuron*, 44(1), 5–21.
11. Maguire, E.A., Gadian, D.G., Johnsrude, I.S., et al. (2000). Navigation-related structural change in the hippocampi of taxi drivers. *Proceedings of the National Academy of Sciences*, 97(8), 4398–4403.
12. Merzenich, M.M., Kaas, J.H., Wall, J., et al. (1983). Topographic reorganization of somatosensory cortical areas 3b and 1 in adult monkeys following restricted deafferentation. *Neuroscience*, 8(1), 33–55.
13. Pascual-Leone, A., Amedi, A., Fregni, F., & Merabet, L.B. (2005). The plastic human brain cortex. *Annual Review of Neuroscience*, 28, 377–401.
14. Pittenger, C., & Duman, R.S. (2008). Stress, depression, and neuroplasticity: A convergence of mechanisms. *Neuropsychopharmacology*, 33(1), 88–109.
15. Sejnowski, T.J., & Destexhe, A. (2000). Why do we sleep? *Brain Research*, 886(1–2), 208–223.
16. Thoenen, H. (1995). Neurotrophins and neuronal plasticity. *Science*, 270(5236), 593–598.
17. Wiesel, T.N. (1982). Postnatal development of the visual cortex and the influence of environment. *Nature*, 299(5884), 583–591.

18. Zatorre, R.J., Fields, R.D., & Johansen-Berg, H. (2012). Plasticity in gray and white: Neuroimaging changes in brain structure during learning. *Nature Neuroscience*, 15(4), 528–536.